Moderna May Be Facing Its Toughest Moment Ever. Time to Sell?

Nov 4, 2023 · Moderna is facing its toughest moment, but the good news is that the company has what it takes -- a solid late-stage pipeline and cash to bring products to market -- to succeed in …

CouponFollow Extension

$10.75
OFF

Is Moderna Stock A No-Brainer Buy On The Sell-Off?

2 weeks from now

Jan 15, 2025 · However, Moderna's enterprise value (EV) is $10.75 billion -- lower than its market cap thanks to a hefty cash stockpile and manageable debt load. If the company can generate …

fool.com

20%
OFF

Moderna Stock Falls 20% In A Month: Time To Sell Or Hold?

2 weeks from now

Oct 16, 2024 · Short-term Investors May Sell MRNA Stock. Moderna, once a financial powerhouse due to its COVID-19 vaccine, feels uncertain regarding its top-line growth after …

nasdaq.com

$500
OFF

Moderna Takes Axe To '24 Sales Guidance, Sending Shares Lower

2 weeks from now

Aug 1, 2024 · Take Moderna, which just chopped $500 million to $1 billion from its 2024 sales forecast—in August—leaving some investors rushing to sell shares. On Thursday, Moderna …

fiercepharma.com

$1
OFF

Moderna Cuts 2025 Sales Forecast By $1 Bln On Weak Vaccine …

2 weeks from now

Jan 13, 2025 · Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) shot and weak demand for COVID-19 …

reuters.com

$1
OFF

Moderna: Fair Value Cut Following Lower 2025 Sales ... - Morningstar

2 weeks from now

Jan 14, 2025 · On Jan.13, Moderna cut its 2025 sales guidance to $1.5 billion-$2.5 billion, down from prior guidance of $2.5 billion-$3.5 billion, partly due to waning covid vaccine demand and …

morningstar.com

$1
OFF

Moderna Cuts 2025 Sales Forecast By $1 Billion On Weak Vaccine …

2 weeks from now

Jan 13, 2025 · Demand for its COVID vaccine has been waning after the pandemic, while adoption of its RSV shot - its second approved product- has been slower than expected, …

yahoo.com

$1
OFF

Moderna Cuts Sales Forecast On Weaker Vaccine Demand - Yahoo …

2 weeks from now

Moderna cut its 2025 forecast by $1 billion Monday, citing weak demand for its newest vaccine as well as slow sales for its COVID-19 vaccine. ... At the same time, we reduced our cash …

yahoo.com

FAQs about Moderna May Be Facing Its Toughest Moment Ever. Time to Sell? Coupon?

Is Moderna facing its toughest moment ever?

To make the world smarter, happier, and richer. Moderna May Be Facing Its Toughest Moment Ever. Time to Sell? Moderna reported a billion-dollar loss in the third quarter and began downsizing its manufacturing infrastructure to match lower levels of vaccine demand. The company says coronavirus vaccine sales may fall further next year. ...

Will 2024 be Moderna's toughest moment ever?

In fact, 2024 may be Moderna's toughest moment ever as vaccine sales reach their lowest point, and new potential products won't yet be able to compensate. Meanwhile, Moderna shares have declined more than 50% this year, even as the company has spoken of promising long-term projects. Does this mean it's time to sell this struggling biotech stock? ...

Does the Motley Fool recommend Moderna?

The Motley Fool recommends Moderna. The Motley Fool has a disclosure policy. After Moderna's Shocking News, Is the Stock a Buy or a Sell? was originally published by The Motley Fool Moderna held its annual R&D day this week. ...

Should you hold on to Moderna if you're already a shareholder?

If you're already a Moderna shareholder, you may be getting impatient -- but as a long-term investor, the best thing you can do right now is hold on. Moderna is facing its toughest moment, but the good news is that the company has what it takes -- a solid late-stage pipeline and cash to bring products to market -- to succeed in the long run. ...

Should you buy Moderna stock now?

If you've held Moderna shares for a while, could lock in a profit if you sold, and are looking to move on to other opportunities, you might consider at least trimming your position. But if you're ready to hold on for a few more years, it could turn out to be a wise move. (And buying the stock now, on the dip, could be a smart move too.) ...

Will Moderna break even in 2028?

And in its update this week, the biotech made significant changes to its strategy. Moderna plans to cut annual research and development (R&D) spending by more than $1 billion starting in 2027 and discontinue five programs -- and it forecast that it would break even in 2028 instead of 2026. ...